Login to Your Account

Poxel’s Imeglimin Boosts Glucose-Sensing in Trial

By Nuala Moran
Staff Writer

Wednesday, October 16, 2013

LONDON – Poxel SA generated new patient data on its diabetes treatment Imeglimin, demonstrating it has a novel mechanism of action and showing the drug could be used in combination with existing orally administered Type II diabetes treatments.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription